{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:09:18Z","timestamp":1749787758168,"version":"3.41.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81400704"],"award-info":[{"award-number":["81400704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060132"],"award-info":[{"award-number":["82060132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Assistance Project of Science and Technology Department of Xinjiang Autonomous Region","award":["2020E0276"],"award-info":[{"award-number":["2020E0276"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Tacrolimus-associated neurologic disorders can be found in some cases, mainly in organ transplantation patients. However, epilepsy induced by tacrolimus in primary membranous nephropathy (PMN) patient is scare.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 63-year-old man experienced 1-year history of foamy urine, and edema of lower extremity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient had proteinuria, hypoalbuminemia, which indicated nephrotic syndrome. Further, we performed renal biopsy for this patient. Combined with the renal biopsy result, the diagnosis of primary membranous nephropathy was established.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>At first, irbesartan was administrated for 6 months. However, the proteinuria had no obvious improvement. Tacrolimus was administrated afterwards.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Twenty-two days after tacrolimus treatment, epilepsy occurred. Sodium valproate and carbamazepine were successively given to control epilepsy. However, the epileptic symptoms were not effectively controlled. During the treatment, the concentration of tacrolimus fluctuated greatly. At last, levetiracetam was given to maintain the curative effect. Fortunately, the patient did not suffer from epilepsy again. The concentration of temporary tacrolimus was stable, whereas proteinuria gradually decreased.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Tacrolimus-induced epilepsy should be considered in patients exhibiting acute neurological symptoms. Early diagnosis and effective treatment play a vital role for favorable prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024989","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T12:35:04Z","timestamp":1614774904000},"page":"e24989","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Tacrolimus-induced epilepsy with primary membranous nephropathy"],"prefix":"10.1097","volume":"100","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin Type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/petr.12198","article-title":"Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience","volume":"18","author":"Xie","year":"2014","journal-title":"Pediatr Transplant"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1432-2277.2008.00780.x","article-title":"Neurologic complications after solid organ transplantation","volume":"22","author":"Senzolo","year":"2009","journal-title":"Transpl Int"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/lt.24035","article-title":"Central nervous system complications after liver transplantation: common but mostly transient phenomena","volume":"21","author":"Bernhardt","year":"2015","journal-title":"Liver Transplant"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1248\/bpb.23.1008","article-title":"Correlation between neurotoxic events and intracerebral concentration of tacrolimus rats","volume":"23","author":"Sakamoto","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00007.x","article-title":"Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients","volume":"48","author":"B\u00f6ttiger","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-0012.2000.140101.x","article-title":"Central nervous system complications in liver transplant recipients\u2013incidence, timing, and long-term follow-up","volume":"14","author":"Bronster","year":"2000","journal-title":"Clin Transplant"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1177\/0300060519883750","article-title":"Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: two case reports","volume":"47","author":"Li","year":"2019","journal-title":"J Int Med Res"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00467-003-1370-3","article-title":"Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome","volume":"19","author":"Loeffler","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"R12-20250612","first-page":"10","article-title":"Recent topics on the mechanisms of immunosuppressive therapy-related neurotoxicities","volume":"20","author":"Zhang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.RES.73.3.596","article-title":"Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling","volume":"73","author":"Lyson","year":"1993","journal-title":"Circ Res"},{"key":"R14-20250612","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.arcmed.2006.07.005","article-title":"Severe neurological events following liver transplantation","volume":"38","author":"Saner","year":"2007","journal-title":"Arch Med Res"},{"key":"R15-20250612","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"R16-20250612","first-page":"205","article-title":"Clinical spectrum of reversible posterior leukoencephalopathy syndrome","volume":"65","author":"Lee","year":"2008","journal-title":"Arch Neurol"},{"key":"R17-20250612","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1590\/1678-4685-jbn-3825","article-title":"Posterior reversible leukoencephalopathy syndrome (PRES) after kidney transplantation: a case report","volume":"40","author":"Davi","year":"2018","journal-title":"J Bras Nefrol"},{"key":"R18-20250612","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/nep.12518","article-title":"Reversible posterior encephalopathy syndrome in children with nephrotic syndrome","volume":"20","author":"Zhou","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"R19-20250612","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197713020-00001","article-title":"Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy","volume":"13","author":"Pinder","year":"1977","journal-title":"Drugs"},{"key":"R20-20250612","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/14656566.2016.1168399","article-title":"Carbamazepine-related antiepileptic drugs for the treatment of epilepsy - a comparative review","volume":"17","author":"Gierbolini","year":"2016","journal-title":"Expert Opin Pharmacother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:57Z","timestamp":1749754857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024989"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024989","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"2020-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}